Evidence map›Paper›PMID 21720547›Full record

ArticlePloS one2011

Endothelial cell-specific molecule 2 (ECSM2) localizes to cell-cell junctions and modulates bFGF-directed cell migration via the ERK-FAK pathway.

Chunwei Shi, Jia Lu, Wen Wu, Fanxin Ma, Joseph Georges, Hanju Huang, James Balducci, Yongchang Chang, Yao Huang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2014
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Chunwei ShiDepartment of Obstetrics and Gynecology, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States of America.
Jia Lu
Wen Wu
Fanxin Ma
Joseph Georges
Hanju Huang
James Balducci
Yongchang Chang
Yao Huang
St. Joseph's Hospital and Medical Center · USHuazhong University of Science and Technology · CNBarrow Neurological Institute · US

Funding

Structural dynamics underlying rho1 GABAC receptor activation and antagonismR01GM085237 · NIGMS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI CHANG, YONGCHANG · 2010 to 2014
$1.2M
NIGMS NIH HHS R01 GM085237
6 · The paper itself

Abstract

backgroundDespite its first discovery by in silico cloning of novel endothelial cell-specific genes a decade ago, the biological functions of endothelial cell-specific molecule 2 (ECSM2) have only recently begun to be understood. Limited data suggest its involvement in cell migration and apoptosis. However, the underlying signaling mechanisms and novel functions of ECSM2 remain to be explored. METHODOLOGY/PRINCIPAL

findingsA rabbit anti-ECSM2 monoclonal antibody (RabMAb) was generated and used to characterize the endogenous ECSM2 protein. Immunoblotting, immunoprecipitation, deglycosylation, immunostaining and confocal microscopy validated that endogenous ECSM2 is a plasma membrane glycoprotein preferentially expressed in vascular endothelial cells (ECs). Expression patterns of heterologously expressed and endogenous ECSM2 identified that ECSM2 was particularly concentrated at cell-cell contacts. Cell aggregation and transwell assays showed that ECSM2 promoted cell-cell adhesion and attenuated basic fibroblast growth factor (bFGF)-driven EC migration. Gain or loss of function assays by overexpression or knockdown of ECSM2 in ECs demonstrated that ECSM2 modulated bFGF-directed EC motility via the FGF receptor (FGFR)-extracellular regulated kinase (ERK)-focal adhesion kinase (FAK) pathway. The counterbalance between FAK tyrosine phosphorylation (activation) and ERK-dependent serine phosphorylation of FAK was critically involved. A model of how ECSM2 signals to impact bFGF/FGFR-driven EC migration was proposed. CONCLUSIONS/SIGNIFICANCE: ECSM2 is likely a novel EC junctional protein. It can promote cell-cell adhesion and inhibit bFGF-mediated cell migration. Mechanistically, ECSM2 attenuates EC motility through the FGFR-ERK-FAK pathway. The findings suggest that ECSM2 could be a key player in coordinating receptor tyrosine kinase (RTK)-, integrin-, and EC junctional component-mediated signaling and may have important implications in disorders related to endothelial dysfunction and impaired EC junction signaling.

Indexed as

Antibodies, MonoclonalApoptosis Regulatory Proteinsbeta CateninCell AdhesionCell AggregationCell LineCell MovementEndothelial CellsExtracellular Signal-Regulated MAP KinasesFibroblast Growth Factor 2Focal Adhesion Protein-Tyrosine KinasesGene Knockdown TechniquesGlycosylationGreen Fluorescent ProteinsHEK293 CellsHumansAntibodies, MonoclonalApoptosis Regulatory Proteinsbeta CateninECSCR protein, humanExtracellular Signal-Regulated MAP KinasesFibroblast Growth Factor 2Focal Adhesion Protein-Tyrosine KinasesGreen Fluorescent ProteinsMembrane ProteinsRecombinant Fusion Proteins

Identifiers

PMID21720547
PMCPMC3123356
OpenAlexW1982907736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.